atenolol

Atenolol is a beta-1 selective adrenergic antagonist that competitively blocks beta-1 receptors predominantly located in cardiac tissue, reducing heart rate, myocardial contractility, and cardiac output while also decreasing renin release from the juxtaglomerular apparatus. This leads to reduced blood pressure and myocardial oxygen demand, making it useful for hypertension, angina, and post-MI management (though less preferred than metoprolol for acute MI due to weaker evidence base). Its cardioselectivity is dose-dependent—at higher doses, beta-1 selectivity is lost and beta-2 blockade can occur, potentially causing bronchospasm in susceptible patients (e.g., asthma/COPD), so caution is still warranted. Pharmacokinetically, atenolol is hydrophilic (low lipid solubility), leading to minimal CNS penetration (less fatigue, depression, and sleep disturbances than propranolol) and primarily renal excretion, requiring dose adjustment in renal impairment. Clinical uses include hypertension, stable angina, and rate control in atrial fibrillation/flutter. Contraindications/cautions include bradycardia, heart block (2nd/3rd degree), decompensated heart failure, and caution in diabetics (can mask hypoglycemia symptoms except sweating). Abrupt discontinuation can cause rebound tachycardia/hypertension and precipitate angina due to upregulation of beta receptors during chronic use. Atenolol is a classic Step 1/Step 2 topic for beta-blocker pharmacology comparisons—particularly noting it is NOT the preferred beta-blocker in acute coronary syndrome (metoprolol/carvedilol preferred), and it lacks intrinsic sympathomimetic activity or alpha-blocking activity found in other beta-blockers like pindolol or carvedilol/labetalol respectively.